



City Research Online

City, University of London Institutional Repository

Citation: Dong, H., Rowland, I., Tuohy, K. M., Thomas, L. & Yaqoob, P. (2010). Effects of *Lactobacillus casei* Shirota on immune function. *Proceedings of the Nutrition Society*, 69(OCE1), E31. doi: 10.1017/s0029665109992199

This is the published version of the paper.

This version of the publication may differ from the final published version.

Permanent repository link: <https://openaccess.city.ac.uk/id/eprint/28463/>

Link to published version: <https://doi.org/10.1017/s0029665109992199>

Copyright: City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to.

Reuse: Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

Effects of *Lactobacillus casei* Shirota on immune function

H. Dong¹, I. Rowland¹, K. M. Tuohy¹, L. Thomas² and P. Yaqoob¹

¹The University of Reading, Reading, UK and ²Yakult UK Ltd, Ruislip, HA4 6QE, UK

Modulation of host immunity is an important potential mechanism by which probiotics confer health benefits⁽¹⁾. The present study was designed to investigate the effect of a probiotic strain *Lactobacillus casei* Shirota (LcS) on the immune function using human peripheral blood mononuclear cells (PBMC) *in vitro*.

PBMC were obtained from eleven healthy adults. LcS were grown in MRS broth (CD0359; Oxoid Ltd, Basingstoke, Hants., UK) anaerobically and harvested in the exponential phase. PBMC (2×10^6 cells/ml) were exposed to three different concentrations of viable LcS for 24 h with or without 2.5 µg concanavalin A (ConA)/ml. The activation markers, CD69 and CD25, on T-cell subsets were assessed by flow cytometry⁽²⁾. Whole blood (WB) or PBMC were stimulated for 24 h by three different concentrations of viable LcS with or without 1 µg lipopolysaccharide (LPS)/ml and cytokines were measured by ELISA⁽³⁾.

In the absence of ConA LcS induced expression of both CD69 and CD25 on CD8+ T-cell subset, but had less effect on CD4+ T-cells and LcS had no further effect on ConA-stimulated cultures (Fig 1). The maximal effect was seen with 10^6 CFU/ml, representing an LcS:PBMC of 1:1. LcS alone induced production of IL-1β, IL-6, TNFα, IL-12 and IL-10, but greatly inhibited LPS-induced IL-10 and IL-6 production (Fig 2). Cytokine production was also measured in WB. Production of cytokines in response to LcS and/or LPS by PBMC and WB was highly correlated (r 0.69–0.83, $P < 0.01$).




Fig. 1. Effect of LcS on CD69 expression by lymphocyte subsets in the presence or absence of ConA.
Mean values were significantly different from those for unstimulated cultures (–LcS, –ConA cultures): ^c $P < 0.001$.




Fig. 2. Effect of LcS on IL-10 production in supernatants of PBMC cultures with or without LPS.

Mean values were significantly different from those for unstimulated cultures (–LcS, –ConA cultures): ^b $P < 0.01$, ^c $P < 0.001$. Mean values were significantly different from those for LPS-stimulated cultures: ^{*} $P < 0.05$.

In the absence of mitogenic stimulation LcS enhances lymphocyte activation, particularly that of cytotoxic T lymphocytes (CD8+ T-cells). The present study is the first to show such an effect of LcS and suggests that LcS could potentiate the destruction of infected cells in the body. LcS also induces both pro-inflammatory and anti-inflammatory cytokine production in the absence of LPS, indicating that LcS could promote cell-mediated immunity and also down regulate inflammation. Further research to investigate the mechanisms is required and human trials are needed to confirm immunomodulation of LcS *in vivo*.

- Galdeano CM, de LeBlanc AD, Vinderola G *et al.* (2007) *Clin Vaccine Immunol* **14**, 485–492.
- Kankaanpää P, Sutas Y, Salminen S *et al.* (2003) *Food Chem* **83**, 269–277.
- Shida K, Suzuki T, Kiyoshima-Shibata J *et al.* (2006) *Clin Vaccine Immunol* **13**, 997–1003.